Floatz logo

Selpercatinib

Infantile Fibrosarcoma

Eli Lilly and CompanySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Infantile Fibrosarcoma cohort.

Asset / SponsorPhaseRating
Larotrectinib
Children's Oncology Group
Phase 2CCC
Larotrectinib
Bayer
D
bay2757556
Bayer
D

Same molecule, other indications

Selpercatinib is also rated in:

medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
soft tissue sarcomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →